Navigation Links
Dependence in Medical Technology

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

... Highlighted at the College on Problems of Drug dependence Annual Meeting RENO, Nev., June 25 ... from the forward-looking statements include dependence on King's ability to conduct its presentations as planned; dependence on the Company's ability to continue to advance ...

Neurocrine Biosciences Presents Elagolix Data

... trials; risk associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial ...

FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain

... trials; risk associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial ...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA XR(TM), ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis

... trials; risk associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for ...

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Neurocrine Biosciences Reports First Quarter 2008 Results

... trials; risk associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial ...

Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Indevus Pharmaceuticals Provides Update on PRO 2000 Program

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results

... trials; risks associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial ...

Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month

... as well as heroin). Local problems with opioid dependence reflect the national data on this growing public ... use of opioid painkillers. Resources for Opioid dependence and Its Treatment Any physician may take the ... who need more information about opioid dependence and its treatment, either for themselves or for ...

Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians

... depression and constipation. When opioid consumption is ongoing, physical dependence can and will develop. This, in turn, can lead to problematic withdrawal ... and non-cancer related, anesthesiologists have the greatest risk of opioid dependence and abuse among health care providers. Also in the high-risk group for ...

Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

... to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks ...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

... resources and access to capital to fund required clinical trials, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks ...

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

... resources and access to capital to fund required clinical trials, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks ...

Prometheus and Rosetta Genomics Announce License and Collaboration Agreement

... to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales and ... to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those ...

Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate

... and commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient ...
Other Contents
(Date:8/31/2014)... Montral, August 31, ... Nature Neuroscience journal by, Sylvain Williams, PhD, and his ... University Institute and McGill University, opens the door towards better ... as well of the role of an essential element of ... In 2009, they developed a unique approach namely, the ...
(Date:8/29/2014)... Until recently, little has been known about what genetic ... team of scientists, one of whom is a University ... showing that genes controlling the development of the brain ... domestication., The study was published Aug. 28 in ... It is online at http://www.sciencemag.org/ ., The domestication ...
(Date:8/29/2014)... the type and number of connections in transcription factor ... robustness in a study published in PLOS Computational ... the assortativity signature contributes to a network,s resilience against ... the out-out assortativity of TFN models has a greater ... three types of assortativity," said Dov A. Pechenick, PhD, ...
Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2
(Date:9/1/2014)... 2014 As well as having completed ... currently pursuing counselor certification in Louisiana. , ... CPI training program as well as the Counselor ... both personally and professionally. I am not only ... able to do so. As a Non Violent ...
(Date:9/1/2014)... September 01, 2014 BCC Research ( ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the global ... in 2013 and is expected to reach $38.7 million ... $471.5 million by 2019, which is equivalent to 64.9% ... The receptor-mediated transport (RMT) segment is forecasted to grow ...
(Date:9/1/2014)... In honor of National Take Your Cat to ... & Referral Center of Minnesota (AERC) is offering a few reasons ... cats. , Many people don’t take their cat to the vet ... but they wouldn’t decide not to take their kid to dentist ... same goes for pets. Just like people want their loved ones ...
(Date:9/1/2014)... Registration is now open for the 4th Annual Harmon Meadow ... held on Sunday, September 21, 2014. The event will be ... Secaucus, New Jersey. All proceeds from the race will benefit ... a sense of self, restoring the family unit, and restoring ... General registration is $30 with special pricing for veterans, military ...
(Date:9/1/2014)... Ontraport , one of the latest ... to automate the small intricacies of managing an online ... prompting an investigative review. , “As a new ... all of the small details involved with running a ... “That’s why Ontraport has become so popular in this ...
Breaking Medicine News(10 mins):Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
Other TagsOther Tags